TY  - JOUR
AU  - Guberina, Maja
AU  - Sak, Ali
AU  - Pöttgen, Christoph
AU  - Tinhofer-Keilholz, Ingeborg
AU  - Budach, Volker
AU  - Balermpas, Panagiotis
AU  - Von der Grün, Jens
AU  - Rödel, Claus Michael
AU  - Gikka, Eleni
AU  - Grosu, Anca-Ligia
AU  - Abdollahi, Amir
AU  - Debus, Jürgen
AU  - Belka, Claus
AU  - Pigorsch, Steffi
AU  - Combs, Stephanie
AU  - Mönnich, David
AU  - Zips, Daniel
AU  - De-Colle, Chiara
AU  - Welz, Stefan
AU  - Linge, Annett
AU  - Lohaus, Fabian
AU  - Baretton, Gustavo
AU  - Gauler, Thomas
AU  - Baumann, Michael
AU  - Krause, Mechthild
AU  - Schuler, Martin
AU  - Bankfalvi, Agnes
AU  - Höing, Benedikt
AU  - Lang, Stephan
AU  - Stuschke, Martin
TI  - ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
JO  - The pharmacogenomics journal
VL  - 21
IS  - 1
SN  - 1473-1150
CY  - Basingstoke
PB  - Nature Publishing Group
M1  - DKFZ-2020-01059
SP  - 37-46
PY  - 2021
N1  - 2021 Feb;21(1):37-46
AB  - Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after definitive concurrent radiochemotherapy is of key importance for the selection for consolidation therapy and for individualized treatment intensification. In this multicenter study we analyzed recurrence-associated single-nucleotide polymorphisms (SNPs) in DNA repair genes in tumor DNA from 132 patients with locally advanced head and neck carcinoma (LadHnSCC). Patients were treated with definitive radiotherapy and simultaneous cisplatin-based chemotherapy at six partner sites of the German Cancer Consortium (DKTK) Radiation Oncology Group from 2005 to 2011. For validation, a group of 20 patients was available. Score selection method using proportional hazard analysis and leave-one-out cross-validation were performed to identify markers associated with outcome. The SNPs rs1799793 and rs13181 were associated with survival and the same SNPs and in addition rs17655 with freedom from loco-regional relapse (ffLRR) in the trainings datasets from all patients. The homozygote major rs1799793 genotype at the ERCC2 gene was associated with better (Hazard ratio (HR): 0.418 (0.234-0.744), p = 0.003) and the homozygote minor rs13181 genotype at ERCC2 with worse survival (HR: 2.074, 95
LB  - PUB:(DE-HGF)16
C6  - pmid:32546699
DO  - DOI:10.1038/s41397-020-0174-1
UR  - https://inrepo02.dkfz.de/record/156721
ER  -